瘦素增强人外周血γδT细胞对肺癌细胞杀伤作用的实验研究
|
摘要
第一部分瘦素增强外周血γδT淋巴细胞杀伤肺癌细胞的作用及其机制研究
目的探讨瘦素在体外对人γδT细胞杀伤作用的影响及可能机制。
方法用异戊烯焦磷酸法体外扩增人外周血γδT细胞,用不同浓度的瘦素诱导培养γδT细胞和人肺腺癌细胞A549细胞。MTT检测γδT细胞增殖。用ERK1/2(细胞外信号调节激酶1/2)特异性抑制剂PD98059阻断ERK1/2信号通路后,分别用Western blot法检测ERK1/2,P-ERK1/2(磷酸化细胞外信号调节激酶1/2)蛋白表达水平;用流式细胞术检测瘦素诱导前后的γδT细胞免疫表型TCR-γδ,CD44,NKG2D(自然杀伤细胞活化性受体)的变化;用乳酸脱氢酶法测定瘦素诱导前后γδT细胞的杀伤活性。
结果γδT细胞培养10天时从扩增前4.21%增加到70.35%,CD44达94.0%。瘦素能够明显促进γδT细胞增殖,并呈浓度依赖性。瘦素可使ERK1/2信号通路中的靶蛋白发生磷酸化激活,用PD98059阻断ERK1/2信号通路信号通路可显著抑制瘦素促细胞的增殖效应,亦可抑制瘦素对γδT细胞ERK1/2蛋白磷酸化。γδT细胞和肺腺癌细胞A549细胞经不同浓度的瘦素诱导48 h后能显著增强γδT细胞A549细胞的杀伤活性(P<0.05)。瘦素促进γδT细胞上TCR-γδ,NKG2D的表达,但对CD44表达无明显影响。
结论瘦素在一定浓度范围内可促进γδT细胞的增殖并增强其杀伤肿瘤细胞作用,瘦素促人γδT细胞增殖效应可能与激活ERK1/2信号通路有关,也可能和其促进细胞高表达NKG2D有关。
第二部分人外周血γδT细胞对裸鼠人肺癌移植瘤的治疗作用
目的探讨人外周血γδT细胞对已建立的A549肺癌裸鼠的过继免疫治疗作用。
方法用人肺癌细胞株A549接种BALB/c裸鼠皮下,建立肺癌裸鼠模型。将已建立肺癌裸鼠模型随机分为两组,对照组用RPMI 1640培养液治疗,治疗组用γδT细胞治疗。从健康人外周血中提取γδT淋巴细胞,体外特异性扩增后浓度调整为5×10~7/ml予0.2ml注入裸鼠腹腔内,观测比较两组种植瘤裸鼠的肿瘤体积、生存时间,并用免疫组化法测定肿瘤组织中c-jun表达。
结果裸鼠接种A549人肺癌细胞(5×10~6/ml)后第14天,在接种部位均有肿瘤形成,直径平均为2.7±0.33mm。在首次治疗后49天时测对照组、治疗组平均肿瘤体积分别为0.97±0.32cm~3、0.46±0.25cm~3,治疗组与对照组比较差异有统计学意义(p﹤0.05)。至75天时对照组种植瘤裸鼠全部死亡,治疗组存活6只,治疗组裸鼠最长存活天数为120天,较对照组存活天数延长,两组生存时间有统计学意义差异(p﹤0.05)。γδΤ细胞治疗组肿瘤组织中c-jun表达多呈弱阳性,2例不表达,而对照组均为阳性表达,两组比较差异有统计学意义(P<0.05)。
结论人外周血γδT细胞对肺癌裸鼠种植瘤具有显著的抑瘤作用,γδT细胞能下调肿瘤组织中c-jun表达,注射γδT细胞的肺癌裸鼠组有更长的生存时间。
PartⅠLeptin Increase the Effect ofγδT Cells Killing on Human Lung Cancer Cell Line A549
Objective To explore the effect of leptin on the cytotoxicity ofγδT in vitro and possible mechanisms.
Methods Use the isopentenyl pyrophosphate method to amplify human peripheral bloodγδT cells in vitro. After theγδT cells and A549 cells were cultured with different concentrations of leptin, MTT method was used to detect the proliferation of the cells .With ERK1 / 2 inhibitor PD98059 blocked ERK1 / 2 signaling pathway, the ERK1 / 2, P-ERK1 / 2 protein levels were observed by the Western blot, to investigate the changes of CD44, NKG2D on surface ofγδT cells by flow cytometry.Meanwhile, the cytotoxicity ofγδT cells on lung cancer cells were measure by lactate dehydrogenase before and after leptin induction.
ResultsγδT cells were amplified from 4.21% to 70.35% in 10 days, CD44 up to 94.0%. Leptin could increase the proliferation ofγδT cells in a dose-dependent manner (P<0.01), but the effect of increasing the proliferation on A549 cells was not obvious.The cytotoxical effects ofγδT Cells on lung cancer cells could be increased afterγδT cells and A549 induced in different concentrations of leptin for 48h.The expression of NKG2D and TCR-γδonγδT cells was up-regulated by treating with leptin but had no effect on CD44 expression.
Conclusions Lepint can enhance the proliferationγδT cells and increase its abilities to kill tumor cells . The cytotoxicity ofγδT cells on cancer cells perhaps be mainly mediated through ERK1/2 pathway and by expresion of NKG2D onγδT.
PartⅡTherapeutic effect of human peripheralγδT cells on human lung cancer xenograft in nude mice
Objective To explore the adoptive immunotherapeutic effect of peripheralγδT cells on nude mice model .
Methods Xenografted animal model of human lung cancer was established by innoculating human lung cancer A549 cells into BALB/c nude mice subcutaneously. They were divided into two groups randomly,γδT cells and control group.γδT cells or RPMI-1640 were respectively injected into abdominal cavity of mice. Tumor volume , expression of c-jun and survival days between two groups were compared.
Results The nude mice inoculated with 5×10~6/ml lung cancer cells.A tumor was observed in the inoculation site after fourteen days later:the volume of formed tumor in two groups was 0.97±0.32cm~3、0.46±0.25 cm~3 respectively in the 49th day of inoculation. It is obvious that the tumor size in the therapeutic group was large than that of control group. Mice in treatment group survived longer than those in the control group (p﹤0.05). There was a significant difference between two groups in expression of c-jun .(p﹤0.05).
ConclusionsγδT cells from human peripheral can inhibit the growth of human lung cancer xenograft in nude mice effectively.γδT cells can down-regulated the c-jun expression of tumor in treatment group. The overall survival between the two nude mice groups was different significantly.
目的探讨瘦素在体外对人γδT细胞杀伤作用的影响及可能机制。
方法用异戊烯焦磷酸法体外扩增人外周血γδT细胞,用不同浓度的瘦素诱导培养γδT细胞和人肺腺癌细胞A549细胞。MTT检测γδT细胞增殖。用ERK1/2(细胞外信号调节激酶1/2)特异性抑制剂PD98059阻断ERK1/2信号通路后,分别用Western blot法检测ERK1/2,P-ERK1/2(磷酸化细胞外信号调节激酶1/2)蛋白表达水平;用流式细胞术检测瘦素诱导前后的γδT细胞免疫表型TCR-γδ,CD44,NKG2D(自然杀伤细胞活化性受体)的变化;用乳酸脱氢酶法测定瘦素诱导前后γδT细胞的杀伤活性。
结果γδT细胞培养10天时从扩增前4.21%增加到70.35%,CD44达94.0%。瘦素能够明显促进γδT细胞增殖,并呈浓度依赖性。瘦素可使ERK1/2信号通路中的靶蛋白发生磷酸化激活,用PD98059阻断ERK1/2信号通路信号通路可显著抑制瘦素促细胞的增殖效应,亦可抑制瘦素对γδT细胞ERK1/2蛋白磷酸化。γδT细胞和肺腺癌细胞A549细胞经不同浓度的瘦素诱导48 h后能显著增强γδT细胞A549细胞的杀伤活性(P<0.05)。瘦素促进γδT细胞上TCR-γδ,NKG2D的表达,但对CD44表达无明显影响。
结论瘦素在一定浓度范围内可促进γδT细胞的增殖并增强其杀伤肿瘤细胞作用,瘦素促人γδT细胞增殖效应可能与激活ERK1/2信号通路有关,也可能和其促进细胞高表达NKG2D有关。
第二部分人外周血γδT细胞对裸鼠人肺癌移植瘤的治疗作用
目的探讨人外周血γδT细胞对已建立的A549肺癌裸鼠的过继免疫治疗作用。
方法用人肺癌细胞株A549接种BALB/c裸鼠皮下,建立肺癌裸鼠模型。将已建立肺癌裸鼠模型随机分为两组,对照组用RPMI 1640培养液治疗,治疗组用γδT细胞治疗。从健康人外周血中提取γδT淋巴细胞,体外特异性扩增后浓度调整为5×10~7/ml予0.2ml注入裸鼠腹腔内,观测比较两组种植瘤裸鼠的肿瘤体积、生存时间,并用免疫组化法测定肿瘤组织中c-jun表达。
结果裸鼠接种A549人肺癌细胞(5×10~6/ml)后第14天,在接种部位均有肿瘤形成,直径平均为2.7±0.33mm。在首次治疗后49天时测对照组、治疗组平均肿瘤体积分别为0.97±0.32cm~3、0.46±0.25cm~3,治疗组与对照组比较差异有统计学意义(p﹤0.05)。至75天时对照组种植瘤裸鼠全部死亡,治疗组存活6只,治疗组裸鼠最长存活天数为120天,较对照组存活天数延长,两组生存时间有统计学意义差异(p﹤0.05)。γδΤ细胞治疗组肿瘤组织中c-jun表达多呈弱阳性,2例不表达,而对照组均为阳性表达,两组比较差异有统计学意义(P<0.05)。
结论人外周血γδT细胞对肺癌裸鼠种植瘤具有显著的抑瘤作用,γδT细胞能下调肿瘤组织中c-jun表达,注射γδT细胞的肺癌裸鼠组有更长的生存时间。
PartⅠLeptin Increase the Effect ofγδT Cells Killing on Human Lung Cancer Cell Line A549
Objective To explore the effect of leptin on the cytotoxicity ofγδT in vitro and possible mechanisms.
Methods Use the isopentenyl pyrophosphate method to amplify human peripheral bloodγδT cells in vitro. After theγδT cells and A549 cells were cultured with different concentrations of leptin, MTT method was used to detect the proliferation of the cells .With ERK1 / 2 inhibitor PD98059 blocked ERK1 / 2 signaling pathway, the ERK1 / 2, P-ERK1 / 2 protein levels were observed by the Western blot, to investigate the changes of CD44, NKG2D on surface ofγδT cells by flow cytometry.Meanwhile, the cytotoxicity ofγδT cells on lung cancer cells were measure by lactate dehydrogenase before and after leptin induction.
ResultsγδT cells were amplified from 4.21% to 70.35% in 10 days, CD44 up to 94.0%. Leptin could increase the proliferation ofγδT cells in a dose-dependent manner (P<0.01), but the effect of increasing the proliferation on A549 cells was not obvious.The cytotoxical effects ofγδT Cells on lung cancer cells could be increased afterγδT cells and A549 induced in different concentrations of leptin for 48h.The expression of NKG2D and TCR-γδonγδT cells was up-regulated by treating with leptin but had no effect on CD44 expression.
Conclusions Lepint can enhance the proliferationγδT cells and increase its abilities to kill tumor cells . The cytotoxicity ofγδT cells on cancer cells perhaps be mainly mediated through ERK1/2 pathway and by expresion of NKG2D onγδT.
PartⅡTherapeutic effect of human peripheralγδT cells on human lung cancer xenograft in nude mice
Objective To explore the adoptive immunotherapeutic effect of peripheralγδT cells on nude mice model .
Methods Xenografted animal model of human lung cancer was established by innoculating human lung cancer A549 cells into BALB/c nude mice subcutaneously. They were divided into two groups randomly,γδT cells and control group.γδT cells or RPMI-1640 were respectively injected into abdominal cavity of mice. Tumor volume , expression of c-jun and survival days between two groups were compared.
Results The nude mice inoculated with 5×10~6/ml lung cancer cells.A tumor was observed in the inoculation site after fourteen days later:the volume of formed tumor in two groups was 0.97±0.32cm~3、0.46±0.25 cm~3 respectively in the 49th day of inoculation. It is obvious that the tumor size in the therapeutic group was large than that of control group. Mice in treatment group survived longer than those in the control group (p﹤0.05). There was a significant difference between two groups in expression of c-jun .(p﹤0.05).
ConclusionsγδT cells from human peripheral can inhibit the growth of human lung cancer xenograft in nude mice effectively.γδT cells can down-regulated the c-jun expression of tumor in treatment group. The overall survival between the two nude mice groups was different significantly.
引文
1. Hardwick JC, Van Den Brink GR, Offerhaus GJ, et al. Leptin is a growth factor for colonic epithelial cells[J]. Gastroenterology, 2001,121(1): 79- 90.
2. Kato Y, Tanaka Y, Miyagawa F, et al. Targeting of tumor cells for humanγδT cells by nonpeptide antigens[J]. J Immunol ,2001,167(9):5092-5098.
3. Tanaka Y.Human gamma delta T cells and tumor immunotherapy. [J].J Clin Exp Hematop. 2006,46(1):11-23.
4.刘军权,韩慧敏,陈复兴.用乳酸脱氢酶试剂盒检测LAK细胞活性[J].临床医学检验, 1995, 13(2):83.
5 Williams G, Harrold J A, Cutler D J, et al.The hypothalamus and the regulation of energy homeosatsis[J]. Proc Nutr Soc,2000,59(3):385-396.
6 La Cava A, Alviggi C,Matarese G..Unraveling the multiple roles of leptin in inflammation and autoimmunity [J]. J Mol Med, 2004, 82(1): 4-11.
7. Howard JK,Lord GM,Matarese G, et al. Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice[J]. J Clin Invest, 1999,104 (8):1051-1059.
8. Martin RC, Santos AJ , Goberna R , et al.Human leptin enhances activation and proliferation of human circulating T lymphocytes [J]. Cell Immunol , 2000 ,199(1):15-24.
9. Zhao, Y., R. Sun, L. You, and Z. Tian. Expression of leptin receptors and response to leptin stimulation of human natural killer cell lines [J].Biochem. Biophys. Res. Commun 2003,300(2): 247-252.
10. Mehdi Fazelial, Hamid Zarkesh-Esfahanie, Zida Wub,et al. Identification of a monoclonal antibody against the leptin receptor that acts as an antagonist and blocks human monocyte and T cell activation. [J]Journal of Immunological Methods. 2006,312,(1-2):190-200.
11. Elizabeth Papathanassoglou, Karim El-Haschimi,et al. Leptin receptor expression and signaling in lymphocytes:kinetics during lymphocyte activation, role in lymphocyte survival, and response to high fat diet in mice.[J]The Journal of Immunology,2006,176(12):7745-7752.
12. KoizumiH,LiuCC,ZhengLM,et al.Expression of perforin and serine esterases by human gamma/delta T cells[J].J Exp Med,1991,173(2):499-502.
13.Chao Wang1, Jun Li1, Huaixin Zheng1, et al.The role of innate immune cells in the response of heat-treated mycobacterium tuberculosis (M.tb)antigens stimulating PBMCs. [J] Cellular & Molecular Immunology.2004;1(6):467-470.
14. Zheng BJ, et al. Anti-tumor effects of human peripheralγδT cells in a mouse tumor model[J]. Int J Cancer ,2001,92:421-425.
15.Wu Y, Wu W, Wong WM, et al. Human {gamma}{delta} T Cells: A Lymphoid Lineage Cell Capable of Professional Phagocytosis. [J] J Immunol. 2009 ,183(9):5622-5629.
16. Faggioni R, Jones-Carson J, Reed D A, et al.Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity:role of tumor necrosis factor alpha and IL-18[J].Proc Natl Acad Sci USA,2000,97(5):2367-2372.
17. Somasundar P,Yu AK,Vona-Davis L,et al.Differential effects of leptin on cancer in vitro[J].J Surg Res,2003,113(1):50-55.
18. Zocchi MR, Ferrarin M, Rugarli C. Selective lysis of the autologous tumor by cTCSlγ/δ+ tumor infiltrating lymphocytes from human lung carcinomas〔J〕.Eur J Immunol , 1990 , 20:2685-2689.
19. Kabelitz D, Wesch D, Pitters E, et al. Characterization of tumor reactivity of human Vγ9Vδ2γδT cells in vitro and in SCID mice in vivo[J]. J Immunol ,2004,173(11):6767-6776.
20. Holderness J, Jackiw L, Kimmel E, et al.Select Plant Tannins Induce IL-2R{alpha} Up-Regulation and Augment Cell Division in {gamma}{delta} T Cells [J ].J Immunol. 2007, 179(10):6468-6478.
21. Anna CG, Freddy GE, Wagner RM , et al. Exogenous leptin restoresin vitro T cellproliferation and cytokine synthesis in patients with common variable immunodeficiency syndrome[J]. Clin Immunol,2005,114(2):147-153.
22. Banks AS, Davis SM, Bates SH, et al. Activation of downstream signals by the long form of the leptin receptor[J]J,Biol Chem,2000, 275(19):14563-14572.
23. Steinberg GR, Watt MJ, Fam BC et al. Ciliary neurotrophic factor suppresses hypothalamic AMP-kinase signaling in leptin-resistant obese mice〔J〕. Endocrinology 147(8):3906-3914.
24. Najib,S, Santos-Alvarez V .Human leptin promotes survival of human circulating blood monocytes prone to apoptosis by activation of P42/44 MAPK pathway .cell immumol.[J]2002,220(2):143.
25.胡建国,侯彦强,李柏青. MAPK信号转导途径在Mtb-Ag激活的γδT细胞杀伤肿瘤细胞中的作用[J].细胞与分子免疫学杂志,2005,21(1) :21-23.
26. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporespon-siveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency[J]. J Clin Invest. 2002,110(8):1093-1103.
27. Spiegelman BM, Flier JS.Obesity and the regulation of energy balance[J]. Cell 2001,104(4):531-543.
28. Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, et al. V gamma 9V delta 2 T cell response to colon carcinoma cells[J]. J Immunol 2005,175(8): 5481-5488.
29. Finzel AH, Reininger AJ, et al. ICAM-1 supports adhesion of human small-cell lung carcinoma to endothelial cells [J].Clin Exp Metastasis, 2004,213, 21(3) :185-189.
30. Scotet E, et al. Tumor recognition following Vγ9Vδ2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipo-proteinA-I[J].J Immunity,2005, 22(1):71-80.
31. Takeuchi O, Akira S. Signaling pathways activated by microorganisms[J].Curr Opin Cell Biol, 2007, 19(2): 185-191.
32. Takeda K, Akira S. Toll-like receptors in innate immunity IntImmunol[J].2005, 17(1): 1-14.
33. Townsend SE, Allison JP.Tumor rejection after directe costimulation of CD8+T cells by B7-transfected melanoma cells[J]. Science, 1993,259(5093):368-370.
34. Dunn, G.P.,A.T. Bruee,H. Ikeda, L.J. Old, and R.D. Cancer immunoediting:from immunosurveillance to tumor escape[J].Nat Immunol,2002, 3(11):991-998.
35. Dalton JE,Pearson J,Scott P,Carding SR.The interaction of gamma delta T cells with activated macrophages is a property of the V gamma 1 subset[J].J Immunol 2003,171(12):6488-6494.
36 .Dalton JE,Howell G,Pearson J,Scott P,Carding SR.Fas-Fas ligand interactions are essential for the binding to and killing of activated macrophages by gamma delta T cells[J].J Immunol 2004;173(6):3660-3667.
37. Wallace PK, Romet-Lemonne JL, Chokri M,Kasper LH, Fanger MW, Fadul CE. Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcgammaRI and the epidermal growth factor receptor[J]. Cancer Immunol Immunother 2000,49(9): 493-503.
38. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation[J]. J Leukoc Biol 2009,86(5): 1065-1073.
39. Harada M,Kimura G,Nomtot Ket al. Heat shock protein and the antitumor T cell response[J].Biotherapy,1998;10(3):22.
40. Tomala J, ChmelovaH, MrkvanT,et al.In vivoexpansion of activated naive CD8+T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as no-vel approach of cancer immunotherapy [ J]. J Immunol,2009, 183(8): 4904-4912.
41. Koizumik, Hojo S, Akashit, et al. Chemokinereceptors in cancer metastasis and cancer cell-derived chemokines in host immune response [J].Cancer Sci, 2007, 98(11): 1652-1658.
42. Holtmeierw ,Kab elitz D. gammadelta T cells link innate and adaptive immune responses [J].Chem Immunol Allergy, 2005, 86:151-183.
43. Caccamo N,Meraviglia S, Ferlazzo V, et al Differential requirements for antigenorhomeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naive,memory and effector T cell subsets [J].Eur JImmunol, 2005,
35(6): 1764-1772.
44. Viey E, Fromont G, Escudier B, et al.Phosphostim-activated gamma delta T cells killautologousmetastatic renal cell carcinoma [J].JImmunol, 2005, 174(3): 1338-1347.
45. Ferrarinim,Helitai S, Pupa S M, et al.Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors [ J].J Natl Cancer Inst,1996, 88(7): 436-441.
46. Fischer S, Scheffler A, Kabelitz D. Activation of humanγδT-cells by heat-treated mistletoe plant extracts[ J].Immunol Lett,1996, 52(2-3): 69-72.
47. Carding S R, Egan P J. Gammadelta T cells:functional plasticity and heterogeneity [J].Nat Rev Immunol, 2002, 2(5): 336-345.
48. Tsuchiya T, Fukuda S, Hamada H, et al. Role of gamma delta T cells in the inflammatory response of experimental colitis mice[J].J Immunol, 2003, 171(10):5507- 5513.
49. Odyniec A, Szczepanik M, Mycko MP, et al. Gamma delta T cells enhance the expression of experimental autoimmune encephalomyelitis by promoting antigen presentation and IL- 12 production[J]. J Immunol, 2004, 173(1): 682- 694.
50. Sato K, Kimura S, Segawa H, et al. Cytotoxic effects ofγδTcells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy[J]. Int J Cancer, 2005,116(1):94-99.
51. Kabelitz D, Wesch D, Pitters E, et al. Characterization of tumor re-activity of human Vγ9Vδ2γδT cells in vitro and in SCID mice in vivo[J].J Immunol,2004,173(11): 6767-6776.
52. Roark CL, Simonian PL, Fontenot AP, et al.γδT cells: an important source of IL-17[J]. Curr Opin Immunol, 2008, 20(3):353-357.
53. Umemura M, Yahagi A, Hamada S, et al. IL-17-mediated regu-lation of innate and acquired immune response against pulmo-nary Mycobacterium bovis bacilleCalmette-Guérin infection[J].J Immunol, 2007, 178(6): 3786-3796.
54. Kabelitz D, Wesch D, He W. Perspectives ofγδT cells in tumor immunology[J]. Cancer Res, 2007, 67(1): 5-8.
55. Corvaisier M,Moreau-aubry A, Diez E, et al V gamma 9V delta 2 T cell response to colon carcinoma cells [J].J Immunol ,2005, 175(8):5481-5488.
56. Todaro M, D, Asaro M, Caccamo N, et a.l.Efficientkilling of human colon cancer stem cellsby gammadelta T lymphocytes [J].J Immunol,2009,182(11): 7287-7296.
57. Guo B L, Liu Z, Aldrich W A, et al. Innate anti-breast cancer immunity of apoptosis resistant humanγδ-T cells[J].Breast Cancer Res Treat,2005,93(2):169-175.
58.陈娟,何维,巴德年,人肿瘤浸润细胞的抗肿瘤活性研究[J] .免疫学杂志2000 , 16(3) 175-178.
59. Viey E, Lucas C, Romagne F, et al.Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cellcarcinoma patients [ J].J Immunother, 2008, 31(3): 313-323.
60. Born WK, Reardon CL, O’Brien RL. The function ofγδTcells in innate immunity, Curr Opin Immunol[J].2006, 18(1):31-38.
61. Girardi M. Immunosurveillance and immunoregulation byγδTcells[J].J Invest Dermatol, 2006, 126(1): 25-31.
62. Scotet E, Martinez L O, Grant E, et al. Tumor recognition fol-lowing Vγ9Vδ2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I[J]. Immunity, 2005, 22(1):71-80.
63. HE X, CHEN H, WU D, et al. Tandem-epitopepeptide: a novel stimulator for gammadeltaT cellsin tumor immunotherapy [J].Cancer Lett, 2010,288(1): 86-93.
64. Burjanadzem,Condominesm,Reme T, et al In vitro expansion of gamma delta T cells withanti-myeloma cellactivity by Phosphostim and IL-2in patients with multiple myeloma [J].Br JHaematol,2007,139(2): 206-216.
65. Zheng BJ,Chan KW,Im S,et al.Anti-tumor effect of human Peripheral gamma delta Tcells in a mouse tumor model[J]. Int J 2001,92:421-425.
66. Kabelitz,D.Wesch,D.Pitters,E.Potential of human gammadelta T lymphocytes for immunotherapy of cancer[J].International Journal of Cancer.2004,112(5):727-731.
67. Girardi M. Immunosurveillance and immunoregulation byγδT cells[J].J Invest Dermatol, 2006, 126(1): 25-31.
68.Arnold R,Seifert M,Asadullah K,et al.Crosstalk between keratinoeytes and T lymphocytes Via Fas/Fas ligand interaetion:modulation by cytokines[J]. J Immunol,1999,162(12):7140-7147.
69. KoizumiH,Liu CC,Zheng LM,et al.Expression of perforin and serine esterases by human gamma/deltaTeells[J]. J ExP Med,1991,173(2):499-502.
70. Sayers TJ,BrooksAD,WardJM,et al.The restrieted expression of granzyme M in human lymphoeytes[J]. J Immunol,2001,166(2):765-771.
71. Klein JL,FiekenseherH,HollidayJE,et al. Herpesvirus saimiri immortalized gammadelta T cell line activated by IL-12[J].J Immunol,1996,156(8):2754-2760.
72. Liu Z, Eltoum I E, Guo B, et al. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer [J].J Immunol ,2008, 180(9): 6044-6053.
73. Kang N, Zhou J, Zhang T, et al.Adoptiveimmunotherapy of lung cancer with immobilizedanti-TCR gammadelta antibody-expanded human gammadelta T-cells in peripheral blood [ J].Cancer B iolTher,2009, 8(16): 1540-1549.
74. Simoni D, Gebbia N, Invidiata F P, et al.Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivoantitumor activity through a gammadelta-Tlymphocytes-mediated activation mechanism [J].JM ed Chem,2008, 51(21): 6800-6807.
75. Dielif, Vermijlen D, Fulfaro F, et al. Targeting human gamma-delta- T-cells with zoledronate and interleukin-2 for immunotherapy of hormone refractory prostate cancer [ J].Cancer Res,2007, 67(15): 7450-7457.
76. Alison T,Garboezi DN. Structure of gamma delta T cell receptors and their recognition of non-peptide antigen[J]. Mol Immunol,2001,38(14):1051-1061.
77. Adrian C,Hayday.γδT Cells:A Right Time and a Right Place for a conserved Third way of Protection[J]. Ann Rev Immunol,2000,18:975-1026.
78. Kong Y, Cao W, Xi X, et al. The NKG2D ligand ULBP4 bindsto TCRgamma9/delta2 and induces cytotoxicity to tumor cellsthrough both TCRgammadelta and NKG2D[J]. Blood, 2009,114(2): 310-317.
79. Finzel A H, Reininger A J, Bode P A, et al. ICAM-1 supportsadhesion of human small-cell lung carcin-oma to endothelial cells[J].Clin Exp Metastasis, 2004, 21(3): 185-189.
80. Rincon-Orozco B, Kunzmann V, Wrobel P, et al. Activation of Vγ9VδT cells by NKG2D[J].JImmunol, 2005, 175(2): 2144-2151.
1.Williams G, Harrold J A, Cutler D J, et al.The hypothalamus and the regulation of energy homeosatsis[J]. Proc Nutr Soc,2000,59(3):385-396.
2.LiMG, DingGL, ChenXJ, et al. Association ofserum and follicular fluid leptin concentrations with granulosa cell phosphorylated signal transducer and activator of transcription 3 expression in fertile patientswith polycystic ovarian syndrome[J]. J Clin Endocrinol Metab, 2007, 92(12): 4771-4476.
3.BergenHT,CherletTC,ManuelP, et a1. Identification of leptin receptors in lung and isolated fetal typeⅡc ells[J].Am J Respir Cell Mol Biol ,2002, 27(1): 1-77.
4.BellmeyerA, Martino JM,Chandel NS, et al.Leptin resistance protects mice from hyperoxia-induced acute lung injury [J].Am J Res Crit CareMed, 2007, 175(6): 587-594.
5.La Cava A, Alviggi C,Matarese G.. Unraveling the multiple roles of leptin in inflammation and autoimmunity [J]. J Mol Med, 2004, 82(1): 4-11.
6.Somasundar P, Mcfadden D W, Hileman S M,et al.Leptin is a growth factor in cancer [J].J Surg Res, 2004, 116(2): 337-349.
7.Bruserud O, HuangTS, Glenjen N, et al. Leptin in human acute myelogenous leukemia:studies ofin vivolevels and in vitroeffects on native functional leukemia blasts[J]. Haematologica, 2002, 87(6):584- 595.
8.Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGFexpression and tumor angiogenesis[J]. Oncogene 2002; 21(13):2000-2008.
9.Soraya Taleb, Olivier Herbin, Hafid Ait-Oufella, et al.Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. [J].Arterioscler Thromb Vasc Biol, 2007, 12,2691-2698.
10.Marnie L. Gruen, Mingming Hao, David W. Piston, et al. Leptin requires canonical migratory signaling pathways for induction of monocyte and macrophage chemotaxis. [J].Am J Physiol Cell Physiol , 2007, 293 (5)1481-1488.
11.Yong-Dae Kim and Heung Man Lee. Leptin upregulates MUC5B expression in human airway epithelial cells via MAPK pathway. [J].Am. J. Respir. Crit. Care Med,2010; 181: 4208-4218.
12 . Lee MP, Orlov D, Sweeney G..Leptin induces rat glomerular mesangial cell hypertrophy, but does not regulate hyperplasia or apoptosis[J].Int J Obes (Lond). 2005 ,29(12):1395-1401.
13.Yamagishi S, Amano S, Inagaki Y, et al. Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties.[J].Microvasc Res, 2003 ;65(3):186-190.
14.Heike Nave, Guenter Mueller, Britta Siegmund, et al. Resistance of Janus Kinase-2 dependent leptin signaling in natural killer (NK) cells: A novel mechanism of NK cell dysfunction in diet-induced obesity. [J]. Endocrinology,2007, 149, ( 7 )3370-3378.
15.Mancuso P, Gotlschalk A, Phare SM,et al.Leptin deficientmice exhibit impaired host defense in gram negative pneumonia.[J].J lmmunol, 2002, 168 (8) : 4018~4024.
16.Armin K. Moshyedi, Michael D. Josephs, Eddie K. Abdalla, et al.Increased leptin expression in mice with bacterial peritonitis is partially regulated by tumor necrosis factor alpha [J]. Infect Immun, 1998, 66, (4) :1800-1802.
17.Bruserud O, Huang TS, Glenjen N, et al. Leptin in human acute myelogenous leukemia:studies of in vivo levels and in vitro effects on native functional leukemia blasts[J]. Haematologica, 2002, 87(6):584- 595.
18.Elinav E,Abd-Elnabi A,Pappo O,et al.Suppression of hepatocellular carcinoma growthin mice via leptin,is associated with inhibition of tumor cell growth and natural killer cell activation[J].J Hepatol,2005,12(3):234-236.
19.Faggioni R, Jones-Carson J, Reed D A, et al.Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity:role of tumor necrosis factor alpha and IL-18[J].Proc Natl Acad Sci USA,2000,97(5):2367-2372.
20.Somasundar P,Yu AK,Vona-Davis L,et al.Differential effects of leptin on cancer in vitro[J].J Surg Res,2003,113(1):50-55.
21.Zumbacnech MS,Boehme MW, Wahl P, et al.Tumor necrosis factor increase serum leptin levels in humans. [J].J clin Endocrinol metab,1997, 82(12):4080-4082.
22.Mantovani G,Maccio A,Madeddu C,et al.Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites[J]. J Mol Med,2001,79(7):406-414.
23.Sanchez MV, Martin RC, Santos AJ, et al. Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action Clin Exp [J].J Immunol, 2003, 133(1): 11-19.
24.Mattioli B, Straface E, Quaranta MG, et al. Leptin promotes differentiation and survival of human dendritic cells and licenses them for Th1 priming[J]. J Immunol, 2005, 174(11): 6820-6828.
25.Raso GM, Pacilio M, Esposito E, et al. Leptin potentiates IFN-gamma induced expression of nitric oxide synthase and cyclo-oxygenase-2 in murine macrophage J774A.1. Br J Pharmacol[J]. 2002, 137(6): 799-804.
26.Loffreda S, Yang S Q, Lin H Z, et al. Leptin regulates proinflammatory immune responses[J]. FASEBJ, 1998, 12(1): 57- 65.
27.Lord GM,MatareseG,Howard JK, et a1.Leptinmodulates the T-cell immune response and reverses starvation·-induced immunosuppression [J].Nature, 1998, 394(6696): 897~901.
28.MitoN,Kitada C,Hosoda T, et a1. Efect of diet induced obesity on ovalbumin- specificimmune response in a murine asthma model [J].Metabolism. 2002, 5l(10): 1241~1246.
29.Tao XN, Zhang XJ, Jin Y, et al. Detection of serum leptin, TNF-αand their correlated analysis in patients with lung cancer[J]. J Clin Intern Med, 2003, 20(8): 416-418.
30.Fenton JI, Hursting SD, Perkins SN, et al. Leptin induces an Apc genotype-associated colon epithelial cell chemokine production pattern associated with macrophage chemotaxis and activation[J]. Carcinogenesis,2007, 8(2): 455-465.
31.Canavan B, Salem RO, Schurgin S, et al. Effects of physiological leptin administration on markers of inflammation, platelet activation, and platelet aggregation during caloric deprivation[J]. J Clin Endocrinol Metab,2005, 90(10): 5779-5785.
32.Kent JW, Comuzzie AG, Mahaney MC, et al. Intercellular adhesion molecule-1 concentration is genetically correlated with insulin resistance, obesity, and HDL concentration in Mexican Americans Diabetes[J]. 2004, 53(10): 2691-2695.
33.Porreca E, Di Febbo C, Fusco L, et al. Soluble thrombomodulin and vascular adhesion molecule-1 are associated to leptin plasma levels in obese women[J]. Atherosclerosis, 2004, 172(1): 175-180.
34.Bates SH, Stearns WH, Dundon TA,et al. STAT3 signalling is required for leptin regulation of energy balance but not reproduction[J]. Nature 2003,421(20):856-859.
35.Bannon AW, Seda J, Carmouche M,etal. Behavioral characterization of neuropeptide Y knockout mice[J]. Brain Res 2000,16(6):79-87.
36.Cascio S,Ferla R,D’Andera A,et al. Expression of angiogenic regulators,VEGF and leptin, is regulated by the EGF/PI3K/STAT3 pathway in colorectal cancer cells[ J].J Cell Physiol,2009, 221(1): 189-194.
37.Banks AS, Davis SM, Bates SH, et al. Activation of downstream signals by the long form of the leptin receptor J Biol Chem[J].2000,275(19):14563-14572.
38.Elizabeth Papathanassoglou,Karim El-Haschimi,Xian Chang Li, et al.Leptin receptor expression and signaling in lymphocytes:kinetics during lymphocyte activation, role in lymphocyte survival, and response to high fat diet in mice.[J]. The Journal of Immunology. 2006, 176: 7745–7752.
39.Jinhua Shen, Isao Sakaida .Leptin enhances TNF-αproduction via p38 and JNK MAPK in LPS-stimulated Kupffer cells.[J].Life Sciences,2005,Volume 77(13):1502-1515 .
40.Onuma M, Bub JD, Rummel TL, et al. Prostate cancer cell-adopocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase[J]. J Biol Chem,2003,278(43):42660- 42667.
41.Kellerer M, Lammers R, Fritsche A, et al. Insulin inhibits leptin receptor signaling in HEK293 cells at the level of janus kinase-2: A potential mechanism for hyper-insulinaemia associated leptin resistance[J]. Diabetologia,2001,44(9):1125-1132.
42.Petridou E,Belechri M,Dessypris N,et al. Leptin and bodymass index in relation to endometrial cancer risk[J]. Ann Nutr Metab, 2002,46(3-4):147-151.
43.Zhao L, Shen ZX, Luo HS, et al. Possible involvement of leptin and leptin-receptor indeveloping gastricadeno-carcinoma[J].World Gastroenterol,2005,11(48):7666-7670.
44.Miyoshi Y, Funahashi T, Tanka S,et al. High expression of leptin receptor mRNA in breast cancer tissues predicts poor prognosis for patients with high, but not low, serum leptin levels[J]. Int J Cancer,2006,118(6):1414-1419.
45.Pair, Lin C, Tran T,et al. Leptin activatesSTAT and ERK2 pathways and induces gastric cancer cell proliferation [J].Biochem BiophysResCommun, 2005, 331(4): 984-992.
46.Ishikawa M, Kitayama J, Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer[J]. Clin Cancer Res, 2004;10(13):4325-4331.
47.Yuan S S, Tsai K B, Chung Y F, et al. Aberrant expression and possible involvement of the leptin receptor in endometrial cancer [J]. Gynecol Oncol, 2004, 92(3) : 769- 775.
48.Kitawaki J, Koshiba H, Ishihara H, et al. Expression of leptin receptor in human endometrium and fluctuation during the menstrual cycle [J]. J Clin Endocrinol Metab, 2000, 85(5) :1946- 1950.
49.Wang SN, Chuang SC, Yeh YT, et al. Potential prognostic value of leptin receptor (Ob-R) in hepatocellular carcinoma[J]. J Clin Pathol, 2006,59(12): 1267-1271.
50.Tsuchiya T, Shimizu H, Horie T,et al. Expression of leptin receptor in lung: Leptin as a growth factor[J]. Eur J Pharmacol, 1999,365(2-3):273-279.
51.Dieudonne M N, Machinal-Quelin F, Serazin-Leroy V, et al.Leptin mediates a proliferative response in human MCF7 breast cancer cells [J]. Biochem Biophys Res Commun, 2002, 293 (1) : 622- 628.
52.Pai R, Lin C, Tran T, et al. Leptin activates STAT and ERK2 pathways and induces gastric cancer cell proliferation [J]. Biochem Biophys Res Commun, 2005, 331(4) : 984- 992.
53.Choi J H, Park S H, Leung P C, et al. Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells [J]. J Clin Endocrinol Metab, 2005, 90(1) : 207-210.
54.Dai-kai,Tian deying,et al. Leptin promote the proliferation and invasion of human hepatocellular carcinoma cell line Huh-7 in vitro.[J].Tumor,2007,27(6):425-428.
55.Lju Z,Uesaka T,Watanabe H,et al.High fat diet enhances colonic cell proliferation and carcinogenesis in rats by elevating serum leptin[J].IntJ Oncol,2001,19(5):1009-1014.
56.Stattin P, Lukanova A, Biessy C, et al.Obesity and colon cancer: does leptin provide a link? [J]. Int J Cancer. 2004,109(1):149-152.
57.Aparicio T, Kotelevets L, Tsocas A, et al. Leptin stimulates the proliferation ofhuman colon cancer cells in vitro but does not promote the growth of colon cancer xenografts in nudemice or intestinal tumorigenesis in Apc( Min/ +) mice[J]. Gut, 2005, 54(8): 1136-1145.
58.Mantovani G,Maccio A,Madeddu C,et al.Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status [J]. 1nt J Cancer, 2002, 98(1): 84~91.
59.Zhu BD, Liu SJ, Liu J, et al. Effect of serum leptin on nutritional status of patients with cancer[J]. J Hygiene Res, 2002, 31(2): 100-102.
60.Fikret Arpaci, Mahmut Ilker Yilmaz, Ahmet Ozet, et al.Low serum leptin level in colon cancer patients without significant weight loss[J]. Tumori 2002,88(2):147-149.
61.Lopez-Soriano J, Curbo N, Tessitore L, et al. Leptin and tumor growth in rats [J]. Int J Cancer, 1999,81(5):726-729.
62.Luo Nanping, Liu Hengguo, et al. Significance of change s of serum NSE and CEA Levels in patients with pneumonia and malignant tumors [J].J of Radio immunology,2008, 21(3),197-199.
63.Tessitore L, Vizio B, Jenkins O, et al. Leptin expression in colorectal and breast cancer patients. [J].Int J Molecular Med, 2000,5(4):421-426.
64.Wang YY, Lin SY. Leptin in relation to hepatocellular carcinoma in patients with liver cirrhosis. [J].Horm Res,2003, 60(4): 185-189.
65.Hu Xing-rong, Deng Zi-hui, XueHui, et al. The clinical value of measurement of serum leptin,α1-acid glycoprotein and alphal-antitrypsine levels in patients with lung cancer[J]. J of Radio Immunology,2010,23(4)363-365.
1 . Holtmeierw,Kabelitz D.Gammadelta T cells link innate and adaptive immune responses[J].Chem Immunol Allergy,2005,86):151-183.
2 . Carding S R, Egan P J. Gammadelta T cells:functional plasticity and heterogeneity[J].Nat Rev Immunol,2002,2(5):336-345.
3.Hayday A C.[gamma][delta]cells: a right time and a right place for a conserved third way of protection[J].Annu Rev Immunol,2000,18:975-1026.
4.Simoni D, Gebbia N, Invidiata F P, et al.Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-Tlymphocytes-mediated activation mechanism [J].J Med Chem,2008, 51(21):6800-6807.
5 . Caccamo N, Dieli F, Meraviglia S, et al.Gammadelta T cell modulation in anticancertreatment [J].Curr Cancer Drug Targets,2010,10(1): 27-36.
6.Wang HY, Lee DA, Peng G et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004,20(1):107-18.
7.Giannopoulos K, Schmitt M, Kowal M et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008,20(3):677-82.
8.D’Alise AM, Auyeung V, Feuerer M et al. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci USA 2008,105 (50):19857-19862.
9.Kabelitz D, Wesch D, Pitters E, et al. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma deltaT cells in vitro and in SCID mice in vivo [J].J Immuno,l2004, 173(11): 6767-6776.
10.Viey E, Fromont G, Escudier B, et al.Phosphostim-activated gamma delta T cells kil autologous metastatic renal cell carcinoma [J].J Immunol,2005, 174(3):1338-1347.
11.Tokuyamah,Hagi T,Mattarollo S R, et al. V gamma 9 V delta 2 T cell cytotoxicity againsttumor cells is enhanced by monoclonal antibody drugs--rituximab andtrastuzumab[J].Int J Cancer,2008,122(11): 2526-2534.
12.Kuroda J, Kimura S, Segawa H, et al. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+leukemia activity of imatinib mesylate [J].Blood Journal,2003,102(6):2229-2235.
13.Ferrarinim,Heltai S, Pupa SM,et al.Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors [J].J Natl Cancer Inst,1996, 88(7): 436-441.
14.Todaro M, D′Asaro M, Caccamo N, et al.Efficient killing of human colon cancer stem cellsby gammadelta T lymphocytes [J].J Immunol,2009, 182(11): 7287-7296.
15.Liu Z, Eltoum I E, Guo B, et al. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mousemodel of prostate cancer [J].J Immuno,l 2008, 180(9): 6044-6053.
16.Kang N, Zhou J, Zhang T, et al. Adoptive immunotherapy of lung cancer with immobilizedanti-TCR gammadelta antibody-expanded human gammadelta T-cells in peripheral blood [J].Cancer BiolTher,2009, 8(16): 1540-1549.
17.Bennouna J,Bompas E,Neidhardt EM, et al. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma [J].Cancer Immunology Immunotherapy,2008, 57(11): 1599-1609.
18.Nakajima J,Murakawa T,Fukamit, et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells[J]Eur J Cardiothorac Surg,2010,37(5):1191-1197.
19.Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human { gamma} delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.[J]Cancer Research,2007,67(15): 7450-7457.
20. Lozupone F, Pende D, Burgio V L, et al. Effect of human natural killer and gammadelta Tcells on the growth of human autologous melanoma xenografts in SCID mice [J].Cancer Res,2004,64(1):378-385.
21.Wilhelm M, Kunzmann V, Eckstein S, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies[J]Blood,2003, 102(1):200-206.
22.Kobayashih,Tanakay,Yagi J, et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study [J]Cancer Immunol Immunother,2007, 56(4): 469-476.
23.Koizumik,Hojo S,Akashit, et al. Chemokinereceptors in cancer metastasis and cancer cell-derived chemokines in host immune response [J].Cancer Sci,2007, 98(11): 1652-1658.
24.Wrobel P, Shojaei H, Schittek B, et al.Lysis of a broad range of epithelial tumour cells byhuman gamma delta T cells: involvement of NKG2D ligands and T-cell receptor-versus NKG2D-dependent recognition [J].Scand JImmunol,2007, 66(2-3): 320-328.
25.Burjanadzem,Condominesm,Reme T, et al. In vitro expansion of gamma delta T cells withanti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma [J].Br J Haematol,2007, 139(2): 206-216.
26.Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self[J]. Nat Immunol, 2005;22(6):345–352.
27.Chakraborty NG, Chattopadhyay S,Mehrotra S, et al.Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. [J]. Hum Immunol,2004,65(8):794–802.
28.Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. [J]. Cell,2008,133(5):775–787.
29.Lauren A. Zenewicz, Andrey Antov,et al.CD4 T-cell differentiation and inflammatory bowel disease. Trends in Molecular Medicine,2009, 15(5):199-207.
30.Siegmund B,Sennello JA,Jones-Carson J,et al.Leptin receptor expression on T lymphocytes modulates chronic intestinal inflammation in mice.[J].Gut.2004 ,53(7):965-972.
31.Viey E, Lucas C, Romagne F, et al.Chemokine receptors expression and migrationpotential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cellcarcinoma patients [J].J Immunother,2008, 31(3):313-323.
32.He X, Chen H, Wu D, et al. Tandem-epitopepeptide: a novel stimulator for gammadelta T cells in tumor immunotherapy [J].Cancer Lett,2010,288(1): 86-93.
33.Anna Carla Goldberg, Freddy Goldberg Eliaschewitz, Wagner Ricardo Montor, et al.Exogenous leptin restores in vitro T cell proliferation and cytokine synthesis in patients with Common Variable Immunodeficiency Syndrome. Clinical Immunology.2005,114(2):147-153.
34 . Abe Y,Muto M, Nieda M, et al. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma [J].Exp Hematol, 2009,37(8): 956-968.
35.Gnantm,Mlineritsch B, Schippingerw, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer[J].N Engl JMed, 2009, 360(7): 679-691.
36.Dudleym E,Wunderlich JR,Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma [J].J C lin Oncol,2005, 23(10): 2346-2357.
37.Weiping Zou. Regulatory T cells, tumour immunity and immunotherapy [J]. Nature Reviews Immunology,2006,6(4):295-307.
38.Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells.[J]. Nat Immunol,2003,4(4):337–42.
39.Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. [J].Nat Rev Immunol,2003;3(3):199–210.
40.Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Ta?in C,Heike T, Valeyre D, Mathian A, NakahatamT, et al. Functional delineation and differentiation dynamics of human CD4+T cells expressing the FoxP3 transcription factor.[J].Immunity 2009;30(6):899–911.
41.ChenJ,Niu HT,He W. Antitumor activity of expanded human tumor–infiltratingγδT lymphocytes[J].Int Arch Allergy Appl Immunol, 2001,125(10):256-263.
42.Zheng BJ,Chan KW,Im S,et al.Anti-tumor effect of human Peripheral gamma delta Tcells in a mouse tumor model. [J]. Int J 2001,92(3):421-425.
43.Poupot M,Pont F,Fournie JJ.Profiling blood Lymphocyte interactions with cancer cells uncovers the inate reactivity of human gamma deltaTcells to anaplastic large cell lymphoma.[J].Immunol,2005;174(3):1717-1722.
44.M. R. Raspollini, F. Castiglione, D. Rossi Degl.Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease free interval in advanced ovaria serous carcinoma.[J].Ann Oncol,2005,16(4):590-596.
45.Meeh PF, King M, O'Brien RL, et al.Charaeteration of the gamma deltaTcell response to acute leukemia.[J].Cancer Immunol Immunother 2006,55(9):1072-1080.
46.Kabelitzd,Weschd,Pitterse,et al.Characterization of tumor reactivity of human
9Vdelta 2gamma delta Tcells in vitro and in SCID mice in vivo.[J]. J lmmunol,2004,173(11):6767-6776.
47.Corvaisier M,Moreau-aubry A, Diez E, et al. V gamma 9V delta 2 T cell response to colon carcinoma cells [J].J Immunol,2005, 175(8):5481-5488.
48.Todaro M, D′Asaro M, Caccamo N, et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes [J].J Immunol,2009, 182(11): 7287-7296.
49.Chen Fuxing,Liu Junquan,Zhang Nanzheng, et al.Anti-tumor effects of the humanγδT Cells,CD3AK cells,CIK cells and DC on nude mice with xenografts of Human gastric carcinoma.[J].Journal of Basic and Clinical Oncology.2009,22(4)277-281.
50.Caccamo N,Merayiglia S, Ferlazzo V, et al. Differential requirements for antigen orhomeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naive,memory and effector T cell subsets [J].Eur J Immunol,2005, 35(6): 1764-1772.
51.Poupotm, Fournie JJ. Non-peptide antigens activating human Vgamma9/Vdelta2 T lymphocytes[J].Immunol Lett,2004, 95(2): 129-138.
52.Qiu fuming,LiZhongpeng,Huang Jian.Resarch progress of cell based immunotherapy. [J].Journal of Zhejiang university.2010,139(4),424-429.
53.Vier E, Lucas C, Romagne F, et al. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients [J].J Immunother,2008, 31(3): 313-323.
54.He X, Chen H, Wu D, et al. Tandem-epitope peptide: a novel stimulator for gammadeltaT cells in tumor immunotherapy [J].Cancer Lett,2010,288(1): 86-93.
55.Diefenbach, A. et al. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nature Immunol.2002,3(11),1142-1149.
56.Wrobel P, Shojaei H, Schittek B, et al. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor-versus NKG2D-dependent recognition [J].Scand J Immunol,2007, 66(2-3): 320-328.
57.Burjanadzem,Condominesm,Reme T, et al. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma [J].Br J Haematol,2007, 139(2): 206-216.
58.Viey E, Fromont G, Escudier B, et al. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma [J].J Immunol,2005,174(3):1338-1347.
59.Tokuyamah,Hagi T,Mattarollo S R, et al. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs-rituximab and trastuzumab [J].Int J Cancer,2008, 122(11): 2526-2534.
60.Kuroda J, Kimura S, Segawa H, et al. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate [J].Blood,2003,102(6): 2229-2235.
61.KoizumiH,LiuCC,ZhengLM,et al.Expression of perforin and serine esterases by human gamma/delta Tcells[J].J Exp Med,1991,173(2):499-502.
62.SayersTJ,BrooksAD,WardJM,et al.The restrieted expression of granzyme M in human lymphoeytes [J].J Immunol,2001,166(2):765-771.
63.Darrin M. Beaupre, Enrique Cepero, Esther A. Obeng, et al.R115777 inducesRas-independent apoptosis of myeloma cells via multiple intrinsic pathways [J] Mol Cancer Ther,2004;3(2):179-186.
2. Kato Y, Tanaka Y, Miyagawa F, et al. Targeting of tumor cells for humanγδT cells by nonpeptide antigens[J]. J Immunol ,2001,167(9):5092-5098.
3. Tanaka Y.Human gamma delta T cells and tumor immunotherapy. [J].J Clin Exp Hematop. 2006,46(1):11-23.
4.刘军权,韩慧敏,陈复兴.用乳酸脱氢酶试剂盒检测LAK细胞活性[J].临床医学检验, 1995, 13(2):83.
5 Williams G, Harrold J A, Cutler D J, et al.The hypothalamus and the regulation of energy homeosatsis[J]. Proc Nutr Soc,2000,59(3):385-396.
6 La Cava A, Alviggi C,Matarese G..Unraveling the multiple roles of leptin in inflammation and autoimmunity [J]. J Mol Med, 2004, 82(1): 4-11.
7. Howard JK,Lord GM,Matarese G, et al. Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice[J]. J Clin Invest, 1999,104 (8):1051-1059.
8. Martin RC, Santos AJ , Goberna R , et al.Human leptin enhances activation and proliferation of human circulating T lymphocytes [J]. Cell Immunol , 2000 ,199(1):15-24.
9. Zhao, Y., R. Sun, L. You, and Z. Tian. Expression of leptin receptors and response to leptin stimulation of human natural killer cell lines [J].Biochem. Biophys. Res. Commun 2003,300(2): 247-252.
10. Mehdi Fazelial, Hamid Zarkesh-Esfahanie, Zida Wub,et al. Identification of a monoclonal antibody against the leptin receptor that acts as an antagonist and blocks human monocyte and T cell activation. [J]Journal of Immunological Methods. 2006,312,(1-2):190-200.
11. Elizabeth Papathanassoglou, Karim El-Haschimi,et al. Leptin receptor expression and signaling in lymphocytes:kinetics during lymphocyte activation, role in lymphocyte survival, and response to high fat diet in mice.[J]The Journal of Immunology,2006,176(12):7745-7752.
12. KoizumiH,LiuCC,ZhengLM,et al.Expression of perforin and serine esterases by human gamma/delta T cells[J].J Exp Med,1991,173(2):499-502.
13.Chao Wang1, Jun Li1, Huaixin Zheng1, et al.The role of innate immune cells in the response of heat-treated mycobacterium tuberculosis (M.tb)antigens stimulating PBMCs. [J] Cellular & Molecular Immunology.2004;1(6):467-470.
14. Zheng BJ, et al. Anti-tumor effects of human peripheralγδT cells in a mouse tumor model[J]. Int J Cancer ,2001,92:421-425.
15.Wu Y, Wu W, Wong WM, et al. Human {gamma}{delta} T Cells: A Lymphoid Lineage Cell Capable of Professional Phagocytosis. [J] J Immunol. 2009 ,183(9):5622-5629.
16. Faggioni R, Jones-Carson J, Reed D A, et al.Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity:role of tumor necrosis factor alpha and IL-18[J].Proc Natl Acad Sci USA,2000,97(5):2367-2372.
17. Somasundar P,Yu AK,Vona-Davis L,et al.Differential effects of leptin on cancer in vitro[J].J Surg Res,2003,113(1):50-55.
18. Zocchi MR, Ferrarin M, Rugarli C. Selective lysis of the autologous tumor by cTCSlγ/δ+ tumor infiltrating lymphocytes from human lung carcinomas〔J〕.Eur J Immunol , 1990 , 20:2685-2689.
19. Kabelitz D, Wesch D, Pitters E, et al. Characterization of tumor reactivity of human Vγ9Vδ2γδT cells in vitro and in SCID mice in vivo[J]. J Immunol ,2004,173(11):6767-6776.
20. Holderness J, Jackiw L, Kimmel E, et al.Select Plant Tannins Induce IL-2R{alpha} Up-Regulation and Augment Cell Division in {gamma}{delta} T Cells [J ].J Immunol. 2007, 179(10):6468-6478.
21. Anna CG, Freddy GE, Wagner RM , et al. Exogenous leptin restoresin vitro T cellproliferation and cytokine synthesis in patients with common variable immunodeficiency syndrome[J]. Clin Immunol,2005,114(2):147-153.
22. Banks AS, Davis SM, Bates SH, et al. Activation of downstream signals by the long form of the leptin receptor[J]J,Biol Chem,2000, 275(19):14563-14572.
23. Steinberg GR, Watt MJ, Fam BC et al. Ciliary neurotrophic factor suppresses hypothalamic AMP-kinase signaling in leptin-resistant obese mice〔J〕. Endocrinology 147(8):3906-3914.
24. Najib,S, Santos-Alvarez V .Human leptin promotes survival of human circulating blood monocytes prone to apoptosis by activation of P42/44 MAPK pathway .cell immumol.[J]2002,220(2):143.
25.胡建国,侯彦强,李柏青. MAPK信号转导途径在Mtb-Ag激活的γδT细胞杀伤肿瘤细胞中的作用[J].细胞与分子免疫学杂志,2005,21(1) :21-23.
26. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporespon-siveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency[J]. J Clin Invest. 2002,110(8):1093-1103.
27. Spiegelman BM, Flier JS.Obesity and the regulation of energy balance[J]. Cell 2001,104(4):531-543.
28. Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, et al. V gamma 9V delta 2 T cell response to colon carcinoma cells[J]. J Immunol 2005,175(8): 5481-5488.
29. Finzel AH, Reininger AJ, et al. ICAM-1 supports adhesion of human small-cell lung carcinoma to endothelial cells [J].Clin Exp Metastasis, 2004,213, 21(3) :185-189.
30. Scotet E, et al. Tumor recognition following Vγ9Vδ2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipo-proteinA-I[J].J Immunity,2005, 22(1):71-80.
31. Takeuchi O, Akira S. Signaling pathways activated by microorganisms[J].Curr Opin Cell Biol, 2007, 19(2): 185-191.
32. Takeda K, Akira S. Toll-like receptors in innate immunity IntImmunol[J].2005, 17(1): 1-14.
33. Townsend SE, Allison JP.Tumor rejection after directe costimulation of CD8+T cells by B7-transfected melanoma cells[J]. Science, 1993,259(5093):368-370.
34. Dunn, G.P.,A.T. Bruee,H. Ikeda, L.J. Old, and R.D. Cancer immunoediting:from immunosurveillance to tumor escape[J].Nat Immunol,2002, 3(11):991-998.
35. Dalton JE,Pearson J,Scott P,Carding SR.The interaction of gamma delta T cells with activated macrophages is a property of the V gamma 1 subset[J].J Immunol 2003,171(12):6488-6494.
36 .Dalton JE,Howell G,Pearson J,Scott P,Carding SR.Fas-Fas ligand interactions are essential for the binding to and killing of activated macrophages by gamma delta T cells[J].J Immunol 2004;173(6):3660-3667.
37. Wallace PK, Romet-Lemonne JL, Chokri M,Kasper LH, Fanger MW, Fadul CE. Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcgammaRI and the epidermal growth factor receptor[J]. Cancer Immunol Immunother 2000,49(9): 493-503.
38. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation[J]. J Leukoc Biol 2009,86(5): 1065-1073.
39. Harada M,Kimura G,Nomtot Ket al. Heat shock protein and the antitumor T cell response[J].Biotherapy,1998;10(3):22.
40. Tomala J, ChmelovaH, MrkvanT,et al.In vivoexpansion of activated naive CD8+T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as no-vel approach of cancer immunotherapy [ J]. J Immunol,2009, 183(8): 4904-4912.
41. Koizumik, Hojo S, Akashit, et al. Chemokinereceptors in cancer metastasis and cancer cell-derived chemokines in host immune response [J].Cancer Sci, 2007, 98(11): 1652-1658.
42. Holtmeierw ,Kab elitz D. gammadelta T cells link innate and adaptive immune responses [J].Chem Immunol Allergy, 2005, 86:151-183.
43. Caccamo N,Meraviglia S, Ferlazzo V, et al Differential requirements for antigenorhomeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naive,memory and effector T cell subsets [J].Eur JImmunol, 2005,
35(6): 1764-1772.
44. Viey E, Fromont G, Escudier B, et al.Phosphostim-activated gamma delta T cells killautologousmetastatic renal cell carcinoma [J].JImmunol, 2005, 174(3): 1338-1347.
45. Ferrarinim,Helitai S, Pupa S M, et al.Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors [ J].J Natl Cancer Inst,1996, 88(7): 436-441.
46. Fischer S, Scheffler A, Kabelitz D. Activation of humanγδT-cells by heat-treated mistletoe plant extracts[ J].Immunol Lett,1996, 52(2-3): 69-72.
47. Carding S R, Egan P J. Gammadelta T cells:functional plasticity and heterogeneity [J].Nat Rev Immunol, 2002, 2(5): 336-345.
48. Tsuchiya T, Fukuda S, Hamada H, et al. Role of gamma delta T cells in the inflammatory response of experimental colitis mice[J].J Immunol, 2003, 171(10):5507- 5513.
49. Odyniec A, Szczepanik M, Mycko MP, et al. Gamma delta T cells enhance the expression of experimental autoimmune encephalomyelitis by promoting antigen presentation and IL- 12 production[J]. J Immunol, 2004, 173(1): 682- 694.
50. Sato K, Kimura S, Segawa H, et al. Cytotoxic effects ofγδTcells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy[J]. Int J Cancer, 2005,116(1):94-99.
51. Kabelitz D, Wesch D, Pitters E, et al. Characterization of tumor re-activity of human Vγ9Vδ2γδT cells in vitro and in SCID mice in vivo[J].J Immunol,2004,173(11): 6767-6776.
52. Roark CL, Simonian PL, Fontenot AP, et al.γδT cells: an important source of IL-17[J]. Curr Opin Immunol, 2008, 20(3):353-357.
53. Umemura M, Yahagi A, Hamada S, et al. IL-17-mediated regu-lation of innate and acquired immune response against pulmo-nary Mycobacterium bovis bacilleCalmette-Guérin infection[J].J Immunol, 2007, 178(6): 3786-3796.
54. Kabelitz D, Wesch D, He W. Perspectives ofγδT cells in tumor immunology[J]. Cancer Res, 2007, 67(1): 5-8.
55. Corvaisier M,Moreau-aubry A, Diez E, et al V gamma 9V delta 2 T cell response to colon carcinoma cells [J].J Immunol ,2005, 175(8):5481-5488.
56. Todaro M, D, Asaro M, Caccamo N, et a.l.Efficientkilling of human colon cancer stem cellsby gammadelta T lymphocytes [J].J Immunol,2009,182(11): 7287-7296.
57. Guo B L, Liu Z, Aldrich W A, et al. Innate anti-breast cancer immunity of apoptosis resistant humanγδ-T cells[J].Breast Cancer Res Treat,2005,93(2):169-175.
58.陈娟,何维,巴德年,人肿瘤浸润细胞的抗肿瘤活性研究[J] .免疫学杂志2000 , 16(3) 175-178.
59. Viey E, Lucas C, Romagne F, et al.Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cellcarcinoma patients [ J].J Immunother, 2008, 31(3): 313-323.
60. Born WK, Reardon CL, O’Brien RL. The function ofγδTcells in innate immunity, Curr Opin Immunol[J].2006, 18(1):31-38.
61. Girardi M. Immunosurveillance and immunoregulation byγδTcells[J].J Invest Dermatol, 2006, 126(1): 25-31.
62. Scotet E, Martinez L O, Grant E, et al. Tumor recognition fol-lowing Vγ9Vδ2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I[J]. Immunity, 2005, 22(1):71-80.
63. HE X, CHEN H, WU D, et al. Tandem-epitopepeptide: a novel stimulator for gammadeltaT cellsin tumor immunotherapy [J].Cancer Lett, 2010,288(1): 86-93.
64. Burjanadzem,Condominesm,Reme T, et al In vitro expansion of gamma delta T cells withanti-myeloma cellactivity by Phosphostim and IL-2in patients with multiple myeloma [J].Br JHaematol,2007,139(2): 206-216.
65. Zheng BJ,Chan KW,Im S,et al.Anti-tumor effect of human Peripheral gamma delta Tcells in a mouse tumor model[J]. Int J 2001,92:421-425.
66. Kabelitz,D.Wesch,D.Pitters,E.Potential of human gammadelta T lymphocytes for immunotherapy of cancer[J].International Journal of Cancer.2004,112(5):727-731.
67. Girardi M. Immunosurveillance and immunoregulation byγδT cells[J].J Invest Dermatol, 2006, 126(1): 25-31.
68.Arnold R,Seifert M,Asadullah K,et al.Crosstalk between keratinoeytes and T lymphocytes Via Fas/Fas ligand interaetion:modulation by cytokines[J]. J Immunol,1999,162(12):7140-7147.
69. KoizumiH,Liu CC,Zheng LM,et al.Expression of perforin and serine esterases by human gamma/deltaTeells[J]. J ExP Med,1991,173(2):499-502.
70. Sayers TJ,BrooksAD,WardJM,et al.The restrieted expression of granzyme M in human lymphoeytes[J]. J Immunol,2001,166(2):765-771.
71. Klein JL,FiekenseherH,HollidayJE,et al. Herpesvirus saimiri immortalized gammadelta T cell line activated by IL-12[J].J Immunol,1996,156(8):2754-2760.
72. Liu Z, Eltoum I E, Guo B, et al. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer [J].J Immunol ,2008, 180(9): 6044-6053.
73. Kang N, Zhou J, Zhang T, et al.Adoptiveimmunotherapy of lung cancer with immobilizedanti-TCR gammadelta antibody-expanded human gammadelta T-cells in peripheral blood [ J].Cancer B iolTher,2009, 8(16): 1540-1549.
74. Simoni D, Gebbia N, Invidiata F P, et al.Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivoantitumor activity through a gammadelta-Tlymphocytes-mediated activation mechanism [J].JM ed Chem,2008, 51(21): 6800-6807.
75. Dielif, Vermijlen D, Fulfaro F, et al. Targeting human gamma-delta- T-cells with zoledronate and interleukin-2 for immunotherapy of hormone refractory prostate cancer [ J].Cancer Res,2007, 67(15): 7450-7457.
76. Alison T,Garboezi DN. Structure of gamma delta T cell receptors and their recognition of non-peptide antigen[J]. Mol Immunol,2001,38(14):1051-1061.
77. Adrian C,Hayday.γδT Cells:A Right Time and a Right Place for a conserved Third way of Protection[J]. Ann Rev Immunol,2000,18:975-1026.
78. Kong Y, Cao W, Xi X, et al. The NKG2D ligand ULBP4 bindsto TCRgamma9/delta2 and induces cytotoxicity to tumor cellsthrough both TCRgammadelta and NKG2D[J]. Blood, 2009,114(2): 310-317.
79. Finzel A H, Reininger A J, Bode P A, et al. ICAM-1 supportsadhesion of human small-cell lung carcin-oma to endothelial cells[J].Clin Exp Metastasis, 2004, 21(3): 185-189.
80. Rincon-Orozco B, Kunzmann V, Wrobel P, et al. Activation of Vγ9VδT cells by NKG2D[J].JImmunol, 2005, 175(2): 2144-2151.
1.Williams G, Harrold J A, Cutler D J, et al.The hypothalamus and the regulation of energy homeosatsis[J]. Proc Nutr Soc,2000,59(3):385-396.
2.LiMG, DingGL, ChenXJ, et al. Association ofserum and follicular fluid leptin concentrations with granulosa cell phosphorylated signal transducer and activator of transcription 3 expression in fertile patientswith polycystic ovarian syndrome[J]. J Clin Endocrinol Metab, 2007, 92(12): 4771-4476.
3.BergenHT,CherletTC,ManuelP, et a1. Identification of leptin receptors in lung and isolated fetal typeⅡc ells[J].Am J Respir Cell Mol Biol ,2002, 27(1): 1-77.
4.BellmeyerA, Martino JM,Chandel NS, et al.Leptin resistance protects mice from hyperoxia-induced acute lung injury [J].Am J Res Crit CareMed, 2007, 175(6): 587-594.
5.La Cava A, Alviggi C,Matarese G.. Unraveling the multiple roles of leptin in inflammation and autoimmunity [J]. J Mol Med, 2004, 82(1): 4-11.
6.Somasundar P, Mcfadden D W, Hileman S M,et al.Leptin is a growth factor in cancer [J].J Surg Res, 2004, 116(2): 337-349.
7.Bruserud O, HuangTS, Glenjen N, et al. Leptin in human acute myelogenous leukemia:studies ofin vivolevels and in vitroeffects on native functional leukemia blasts[J]. Haematologica, 2002, 87(6):584- 595.
8.Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGFexpression and tumor angiogenesis[J]. Oncogene 2002; 21(13):2000-2008.
9.Soraya Taleb, Olivier Herbin, Hafid Ait-Oufella, et al.Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. [J].Arterioscler Thromb Vasc Biol, 2007, 12,2691-2698.
10.Marnie L. Gruen, Mingming Hao, David W. Piston, et al. Leptin requires canonical migratory signaling pathways for induction of monocyte and macrophage chemotaxis. [J].Am J Physiol Cell Physiol , 2007, 293 (5)1481-1488.
11.Yong-Dae Kim and Heung Man Lee. Leptin upregulates MUC5B expression in human airway epithelial cells via MAPK pathway. [J].Am. J. Respir. Crit. Care Med,2010; 181: 4208-4218.
12 . Lee MP, Orlov D, Sweeney G..Leptin induces rat glomerular mesangial cell hypertrophy, but does not regulate hyperplasia or apoptosis[J].Int J Obes (Lond). 2005 ,29(12):1395-1401.
13.Yamagishi S, Amano S, Inagaki Y, et al. Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties.[J].Microvasc Res, 2003 ;65(3):186-190.
14.Heike Nave, Guenter Mueller, Britta Siegmund, et al. Resistance of Janus Kinase-2 dependent leptin signaling in natural killer (NK) cells: A novel mechanism of NK cell dysfunction in diet-induced obesity. [J]. Endocrinology,2007, 149, ( 7 )3370-3378.
15.Mancuso P, Gotlschalk A, Phare SM,et al.Leptin deficientmice exhibit impaired host defense in gram negative pneumonia.[J].J lmmunol, 2002, 168 (8) : 4018~4024.
16.Armin K. Moshyedi, Michael D. Josephs, Eddie K. Abdalla, et al.Increased leptin expression in mice with bacterial peritonitis is partially regulated by tumor necrosis factor alpha [J]. Infect Immun, 1998, 66, (4) :1800-1802.
17.Bruserud O, Huang TS, Glenjen N, et al. Leptin in human acute myelogenous leukemia:studies of in vivo levels and in vitro effects on native functional leukemia blasts[J]. Haematologica, 2002, 87(6):584- 595.
18.Elinav E,Abd-Elnabi A,Pappo O,et al.Suppression of hepatocellular carcinoma growthin mice via leptin,is associated with inhibition of tumor cell growth and natural killer cell activation[J].J Hepatol,2005,12(3):234-236.
19.Faggioni R, Jones-Carson J, Reed D A, et al.Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity:role of tumor necrosis factor alpha and IL-18[J].Proc Natl Acad Sci USA,2000,97(5):2367-2372.
20.Somasundar P,Yu AK,Vona-Davis L,et al.Differential effects of leptin on cancer in vitro[J].J Surg Res,2003,113(1):50-55.
21.Zumbacnech MS,Boehme MW, Wahl P, et al.Tumor necrosis factor increase serum leptin levels in humans. [J].J clin Endocrinol metab,1997, 82(12):4080-4082.
22.Mantovani G,Maccio A,Madeddu C,et al.Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites[J]. J Mol Med,2001,79(7):406-414.
23.Sanchez MV, Martin RC, Santos AJ, et al. Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action Clin Exp [J].J Immunol, 2003, 133(1): 11-19.
24.Mattioli B, Straface E, Quaranta MG, et al. Leptin promotes differentiation and survival of human dendritic cells and licenses them for Th1 priming[J]. J Immunol, 2005, 174(11): 6820-6828.
25.Raso GM, Pacilio M, Esposito E, et al. Leptin potentiates IFN-gamma induced expression of nitric oxide synthase and cyclo-oxygenase-2 in murine macrophage J774A.1. Br J Pharmacol[J]. 2002, 137(6): 799-804.
26.Loffreda S, Yang S Q, Lin H Z, et al. Leptin regulates proinflammatory immune responses[J]. FASEBJ, 1998, 12(1): 57- 65.
27.Lord GM,MatareseG,Howard JK, et a1.Leptinmodulates the T-cell immune response and reverses starvation·-induced immunosuppression [J].Nature, 1998, 394(6696): 897~901.
28.MitoN,Kitada C,Hosoda T, et a1. Efect of diet induced obesity on ovalbumin- specificimmune response in a murine asthma model [J].Metabolism. 2002, 5l(10): 1241~1246.
29.Tao XN, Zhang XJ, Jin Y, et al. Detection of serum leptin, TNF-αand their correlated analysis in patients with lung cancer[J]. J Clin Intern Med, 2003, 20(8): 416-418.
30.Fenton JI, Hursting SD, Perkins SN, et al. Leptin induces an Apc genotype-associated colon epithelial cell chemokine production pattern associated with macrophage chemotaxis and activation[J]. Carcinogenesis,2007, 8(2): 455-465.
31.Canavan B, Salem RO, Schurgin S, et al. Effects of physiological leptin administration on markers of inflammation, platelet activation, and platelet aggregation during caloric deprivation[J]. J Clin Endocrinol Metab,2005, 90(10): 5779-5785.
32.Kent JW, Comuzzie AG, Mahaney MC, et al. Intercellular adhesion molecule-1 concentration is genetically correlated with insulin resistance, obesity, and HDL concentration in Mexican Americans Diabetes[J]. 2004, 53(10): 2691-2695.
33.Porreca E, Di Febbo C, Fusco L, et al. Soluble thrombomodulin and vascular adhesion molecule-1 are associated to leptin plasma levels in obese women[J]. Atherosclerosis, 2004, 172(1): 175-180.
34.Bates SH, Stearns WH, Dundon TA,et al. STAT3 signalling is required for leptin regulation of energy balance but not reproduction[J]. Nature 2003,421(20):856-859.
35.Bannon AW, Seda J, Carmouche M,etal. Behavioral characterization of neuropeptide Y knockout mice[J]. Brain Res 2000,16(6):79-87.
36.Cascio S,Ferla R,D’Andera A,et al. Expression of angiogenic regulators,VEGF and leptin, is regulated by the EGF/PI3K/STAT3 pathway in colorectal cancer cells[ J].J Cell Physiol,2009, 221(1): 189-194.
37.Banks AS, Davis SM, Bates SH, et al. Activation of downstream signals by the long form of the leptin receptor J Biol Chem[J].2000,275(19):14563-14572.
38.Elizabeth Papathanassoglou,Karim El-Haschimi,Xian Chang Li, et al.Leptin receptor expression and signaling in lymphocytes:kinetics during lymphocyte activation, role in lymphocyte survival, and response to high fat diet in mice.[J]. The Journal of Immunology. 2006, 176: 7745–7752.
39.Jinhua Shen, Isao Sakaida .Leptin enhances TNF-αproduction via p38 and JNK MAPK in LPS-stimulated Kupffer cells.[J].Life Sciences,2005,Volume 77(13):1502-1515 .
40.Onuma M, Bub JD, Rummel TL, et al. Prostate cancer cell-adopocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase[J]. J Biol Chem,2003,278(43):42660- 42667.
41.Kellerer M, Lammers R, Fritsche A, et al. Insulin inhibits leptin receptor signaling in HEK293 cells at the level of janus kinase-2: A potential mechanism for hyper-insulinaemia associated leptin resistance[J]. Diabetologia,2001,44(9):1125-1132.
42.Petridou E,Belechri M,Dessypris N,et al. Leptin and bodymass index in relation to endometrial cancer risk[J]. Ann Nutr Metab, 2002,46(3-4):147-151.
43.Zhao L, Shen ZX, Luo HS, et al. Possible involvement of leptin and leptin-receptor indeveloping gastricadeno-carcinoma[J].World Gastroenterol,2005,11(48):7666-7670.
44.Miyoshi Y, Funahashi T, Tanka S,et al. High expression of leptin receptor mRNA in breast cancer tissues predicts poor prognosis for patients with high, but not low, serum leptin levels[J]. Int J Cancer,2006,118(6):1414-1419.
45.Pair, Lin C, Tran T,et al. Leptin activatesSTAT and ERK2 pathways and induces gastric cancer cell proliferation [J].Biochem BiophysResCommun, 2005, 331(4): 984-992.
46.Ishikawa M, Kitayama J, Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer[J]. Clin Cancer Res, 2004;10(13):4325-4331.
47.Yuan S S, Tsai K B, Chung Y F, et al. Aberrant expression and possible involvement of the leptin receptor in endometrial cancer [J]. Gynecol Oncol, 2004, 92(3) : 769- 775.
48.Kitawaki J, Koshiba H, Ishihara H, et al. Expression of leptin receptor in human endometrium and fluctuation during the menstrual cycle [J]. J Clin Endocrinol Metab, 2000, 85(5) :1946- 1950.
49.Wang SN, Chuang SC, Yeh YT, et al. Potential prognostic value of leptin receptor (Ob-R) in hepatocellular carcinoma[J]. J Clin Pathol, 2006,59(12): 1267-1271.
50.Tsuchiya T, Shimizu H, Horie T,et al. Expression of leptin receptor in lung: Leptin as a growth factor[J]. Eur J Pharmacol, 1999,365(2-3):273-279.
51.Dieudonne M N, Machinal-Quelin F, Serazin-Leroy V, et al.Leptin mediates a proliferative response in human MCF7 breast cancer cells [J]. Biochem Biophys Res Commun, 2002, 293 (1) : 622- 628.
52.Pai R, Lin C, Tran T, et al. Leptin activates STAT and ERK2 pathways and induces gastric cancer cell proliferation [J]. Biochem Biophys Res Commun, 2005, 331(4) : 984- 992.
53.Choi J H, Park S H, Leung P C, et al. Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells [J]. J Clin Endocrinol Metab, 2005, 90(1) : 207-210.
54.Dai-kai,Tian deying,et al. Leptin promote the proliferation and invasion of human hepatocellular carcinoma cell line Huh-7 in vitro.[J].Tumor,2007,27(6):425-428.
55.Lju Z,Uesaka T,Watanabe H,et al.High fat diet enhances colonic cell proliferation and carcinogenesis in rats by elevating serum leptin[J].IntJ Oncol,2001,19(5):1009-1014.
56.Stattin P, Lukanova A, Biessy C, et al.Obesity and colon cancer: does leptin provide a link? [J]. Int J Cancer. 2004,109(1):149-152.
57.Aparicio T, Kotelevets L, Tsocas A, et al. Leptin stimulates the proliferation ofhuman colon cancer cells in vitro but does not promote the growth of colon cancer xenografts in nudemice or intestinal tumorigenesis in Apc( Min/ +) mice[J]. Gut, 2005, 54(8): 1136-1145.
58.Mantovani G,Maccio A,Madeddu C,et al.Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status [J]. 1nt J Cancer, 2002, 98(1): 84~91.
59.Zhu BD, Liu SJ, Liu J, et al. Effect of serum leptin on nutritional status of patients with cancer[J]. J Hygiene Res, 2002, 31(2): 100-102.
60.Fikret Arpaci, Mahmut Ilker Yilmaz, Ahmet Ozet, et al.Low serum leptin level in colon cancer patients without significant weight loss[J]. Tumori 2002,88(2):147-149.
61.Lopez-Soriano J, Curbo N, Tessitore L, et al. Leptin and tumor growth in rats [J]. Int J Cancer, 1999,81(5):726-729.
62.Luo Nanping, Liu Hengguo, et al. Significance of change s of serum NSE and CEA Levels in patients with pneumonia and malignant tumors [J].J of Radio immunology,2008, 21(3),197-199.
63.Tessitore L, Vizio B, Jenkins O, et al. Leptin expression in colorectal and breast cancer patients. [J].Int J Molecular Med, 2000,5(4):421-426.
64.Wang YY, Lin SY. Leptin in relation to hepatocellular carcinoma in patients with liver cirrhosis. [J].Horm Res,2003, 60(4): 185-189.
65.Hu Xing-rong, Deng Zi-hui, XueHui, et al. The clinical value of measurement of serum leptin,α1-acid glycoprotein and alphal-antitrypsine levels in patients with lung cancer[J]. J of Radio Immunology,2010,23(4)363-365.
1 . Holtmeierw,Kabelitz D.Gammadelta T cells link innate and adaptive immune responses[J].Chem Immunol Allergy,2005,86):151-183.
2 . Carding S R, Egan P J. Gammadelta T cells:functional plasticity and heterogeneity[J].Nat Rev Immunol,2002,2(5):336-345.
3.Hayday A C.[gamma][delta]cells: a right time and a right place for a conserved third way of protection[J].Annu Rev Immunol,2000,18:975-1026.
4.Simoni D, Gebbia N, Invidiata F P, et al.Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-Tlymphocytes-mediated activation mechanism [J].J Med Chem,2008, 51(21):6800-6807.
5 . Caccamo N, Dieli F, Meraviglia S, et al.Gammadelta T cell modulation in anticancertreatment [J].Curr Cancer Drug Targets,2010,10(1): 27-36.
6.Wang HY, Lee DA, Peng G et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004,20(1):107-18.
7.Giannopoulos K, Schmitt M, Kowal M et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008,20(3):677-82.
8.D’Alise AM, Auyeung V, Feuerer M et al. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci USA 2008,105 (50):19857-19862.
9.Kabelitz D, Wesch D, Pitters E, et al. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma deltaT cells in vitro and in SCID mice in vivo [J].J Immuno,l2004, 173(11): 6767-6776.
10.Viey E, Fromont G, Escudier B, et al.Phosphostim-activated gamma delta T cells kil autologous metastatic renal cell carcinoma [J].J Immunol,2005, 174(3):1338-1347.
11.Tokuyamah,Hagi T,Mattarollo S R, et al. V gamma 9 V delta 2 T cell cytotoxicity againsttumor cells is enhanced by monoclonal antibody drugs--rituximab andtrastuzumab[J].Int J Cancer,2008,122(11): 2526-2534.
12.Kuroda J, Kimura S, Segawa H, et al. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+leukemia activity of imatinib mesylate [J].Blood Journal,2003,102(6):2229-2235.
13.Ferrarinim,Heltai S, Pupa SM,et al.Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors [J].J Natl Cancer Inst,1996, 88(7): 436-441.
14.Todaro M, D′Asaro M, Caccamo N, et al.Efficient killing of human colon cancer stem cellsby gammadelta T lymphocytes [J].J Immunol,2009, 182(11): 7287-7296.
15.Liu Z, Eltoum I E, Guo B, et al. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mousemodel of prostate cancer [J].J Immuno,l 2008, 180(9): 6044-6053.
16.Kang N, Zhou J, Zhang T, et al. Adoptive immunotherapy of lung cancer with immobilizedanti-TCR gammadelta antibody-expanded human gammadelta T-cells in peripheral blood [J].Cancer BiolTher,2009, 8(16): 1540-1549.
17.Bennouna J,Bompas E,Neidhardt EM, et al. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma [J].Cancer Immunology Immunotherapy,2008, 57(11): 1599-1609.
18.Nakajima J,Murakawa T,Fukamit, et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells[J]Eur J Cardiothorac Surg,2010,37(5):1191-1197.
19.Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human { gamma} delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.[J]Cancer Research,2007,67(15): 7450-7457.
20. Lozupone F, Pende D, Burgio V L, et al. Effect of human natural killer and gammadelta Tcells on the growth of human autologous melanoma xenografts in SCID mice [J].Cancer Res,2004,64(1):378-385.
21.Wilhelm M, Kunzmann V, Eckstein S, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies[J]Blood,2003, 102(1):200-206.
22.Kobayashih,Tanakay,Yagi J, et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study [J]Cancer Immunol Immunother,2007, 56(4): 469-476.
23.Koizumik,Hojo S,Akashit, et al. Chemokinereceptors in cancer metastasis and cancer cell-derived chemokines in host immune response [J].Cancer Sci,2007, 98(11): 1652-1658.
24.Wrobel P, Shojaei H, Schittek B, et al.Lysis of a broad range of epithelial tumour cells byhuman gamma delta T cells: involvement of NKG2D ligands and T-cell receptor-versus NKG2D-dependent recognition [J].Scand JImmunol,2007, 66(2-3): 320-328.
25.Burjanadzem,Condominesm,Reme T, et al. In vitro expansion of gamma delta T cells withanti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma [J].Br J Haematol,2007, 139(2): 206-216.
26.Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self[J]. Nat Immunol, 2005;22(6):345–352.
27.Chakraborty NG, Chattopadhyay S,Mehrotra S, et al.Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. [J]. Hum Immunol,2004,65(8):794–802.
28.Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. [J]. Cell,2008,133(5):775–787.
29.Lauren A. Zenewicz, Andrey Antov,et al.CD4 T-cell differentiation and inflammatory bowel disease. Trends in Molecular Medicine,2009, 15(5):199-207.
30.Siegmund B,Sennello JA,Jones-Carson J,et al.Leptin receptor expression on T lymphocytes modulates chronic intestinal inflammation in mice.[J].Gut.2004 ,53(7):965-972.
31.Viey E, Lucas C, Romagne F, et al.Chemokine receptors expression and migrationpotential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cellcarcinoma patients [J].J Immunother,2008, 31(3):313-323.
32.He X, Chen H, Wu D, et al. Tandem-epitopepeptide: a novel stimulator for gammadelta T cells in tumor immunotherapy [J].Cancer Lett,2010,288(1): 86-93.
33.Anna Carla Goldberg, Freddy Goldberg Eliaschewitz, Wagner Ricardo Montor, et al.Exogenous leptin restores in vitro T cell proliferation and cytokine synthesis in patients with Common Variable Immunodeficiency Syndrome. Clinical Immunology.2005,114(2):147-153.
34 . Abe Y,Muto M, Nieda M, et al. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma [J].Exp Hematol, 2009,37(8): 956-968.
35.Gnantm,Mlineritsch B, Schippingerw, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer[J].N Engl JMed, 2009, 360(7): 679-691.
36.Dudleym E,Wunderlich JR,Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma [J].J C lin Oncol,2005, 23(10): 2346-2357.
37.Weiping Zou. Regulatory T cells, tumour immunity and immunotherapy [J]. Nature Reviews Immunology,2006,6(4):295-307.
38.Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells.[J]. Nat Immunol,2003,4(4):337–42.
39.Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. [J].Nat Rev Immunol,2003;3(3):199–210.
40.Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Ta?in C,Heike T, Valeyre D, Mathian A, NakahatamT, et al. Functional delineation and differentiation dynamics of human CD4+T cells expressing the FoxP3 transcription factor.[J].Immunity 2009;30(6):899–911.
41.ChenJ,Niu HT,He W. Antitumor activity of expanded human tumor–infiltratingγδT lymphocytes[J].Int Arch Allergy Appl Immunol, 2001,125(10):256-263.
42.Zheng BJ,Chan KW,Im S,et al.Anti-tumor effect of human Peripheral gamma delta Tcells in a mouse tumor model. [J]. Int J 2001,92(3):421-425.
43.Poupot M,Pont F,Fournie JJ.Profiling blood Lymphocyte interactions with cancer cells uncovers the inate reactivity of human gamma deltaTcells to anaplastic large cell lymphoma.[J].Immunol,2005;174(3):1717-1722.
44.M. R. Raspollini, F. Castiglione, D. Rossi Degl.Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease free interval in advanced ovaria serous carcinoma.[J].Ann Oncol,2005,16(4):590-596.
45.Meeh PF, King M, O'Brien RL, et al.Charaeteration of the gamma deltaTcell response to acute leukemia.[J].Cancer Immunol Immunother 2006,55(9):1072-1080.
46.Kabelitzd,Weschd,Pitterse,et al.Characterization of tumor reactivity of human
9Vdelta 2gamma delta Tcells in vitro and in SCID mice in vivo.[J]. J lmmunol,2004,173(11):6767-6776.
47.Corvaisier M,Moreau-aubry A, Diez E, et al. V gamma 9V delta 2 T cell response to colon carcinoma cells [J].J Immunol,2005, 175(8):5481-5488.
48.Todaro M, D′Asaro M, Caccamo N, et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes [J].J Immunol,2009, 182(11): 7287-7296.
49.Chen Fuxing,Liu Junquan,Zhang Nanzheng, et al.Anti-tumor effects of the humanγδT Cells,CD3AK cells,CIK cells and DC on nude mice with xenografts of Human gastric carcinoma.[J].Journal of Basic and Clinical Oncology.2009,22(4)277-281.
50.Caccamo N,Merayiglia S, Ferlazzo V, et al. Differential requirements for antigen orhomeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naive,memory and effector T cell subsets [J].Eur J Immunol,2005, 35(6): 1764-1772.
51.Poupotm, Fournie JJ. Non-peptide antigens activating human Vgamma9/Vdelta2 T lymphocytes[J].Immunol Lett,2004, 95(2): 129-138.
52.Qiu fuming,LiZhongpeng,Huang Jian.Resarch progress of cell based immunotherapy. [J].Journal of Zhejiang university.2010,139(4),424-429.
53.Vier E, Lucas C, Romagne F, et al. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients [J].J Immunother,2008, 31(3): 313-323.
54.He X, Chen H, Wu D, et al. Tandem-epitope peptide: a novel stimulator for gammadeltaT cells in tumor immunotherapy [J].Cancer Lett,2010,288(1): 86-93.
55.Diefenbach, A. et al. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nature Immunol.2002,3(11),1142-1149.
56.Wrobel P, Shojaei H, Schittek B, et al. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor-versus NKG2D-dependent recognition [J].Scand J Immunol,2007, 66(2-3): 320-328.
57.Burjanadzem,Condominesm,Reme T, et al. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma [J].Br J Haematol,2007, 139(2): 206-216.
58.Viey E, Fromont G, Escudier B, et al. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma [J].J Immunol,2005,174(3):1338-1347.
59.Tokuyamah,Hagi T,Mattarollo S R, et al. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs-rituximab and trastuzumab [J].Int J Cancer,2008, 122(11): 2526-2534.
60.Kuroda J, Kimura S, Segawa H, et al. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate [J].Blood,2003,102(6): 2229-2235.
61.KoizumiH,LiuCC,ZhengLM,et al.Expression of perforin and serine esterases by human gamma/delta Tcells[J].J Exp Med,1991,173(2):499-502.
62.SayersTJ,BrooksAD,WardJM,et al.The restrieted expression of granzyme M in human lymphoeytes [J].J Immunol,2001,166(2):765-771.
63.Darrin M. Beaupre, Enrique Cepero, Esther A. Obeng, et al.R115777 inducesRas-independent apoptosis of myeloma cells via multiple intrinsic pathways [J] Mol Cancer Ther,2004;3(2):179-186.